You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥(01093.HK)兩款丁苯(酉太)產品明年3月底價下降逾五成
阿思達克 12-28 12:33
石藥集團(01093.HK)公布,已就丁苯(酉太)軟膠囊及丁苯(酉太)氯化鈉注射液的醫保支付標準參與國家醫保局談判,兩款產品新醫保支付標準分別定為每粒3.36元人民幣(下同)及每支139元,較目前的全國最低售價分別降低55.6%及51.3%,新定價於2021年3月1日起生效。

公司表示,該等產品的全國售價將會相應調整至新醫保支付標準的水平,預期售價下調會在一定時期內對該等產品的未來收入帶來下降壓力,但同時亦會提高產品的可負擔性,料刺激需求,帶動銷量增長,一定程度上彌補價格下降對收入的影響。石藥表示,本次醫保談判完成亦可能會加快該等產品的醫院准入,並化解其被列入國家和各省市集中帶量採購的風險,現階段尚不確定醫保支付標準調整對集團可能產生的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account